An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Pelin Kaya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 6, Sildenafil Citrate, Proto-Oncogene Proteins p21(ras), Cell Proliferation. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds National de la Recherche Luxembourg, Bayer-Stiftungen.
Abstract (Originalsprache)
The trafficking chaperone PDE6D (or PDEδ) was proposed as a surrogate target for K-Ras, leading to the development of a series of inhibitors that block its prenyl binding pocket. These inhibitors suffered from low solubility and suspected off-target effects, preventing their clinical development. Here, we developed a highly soluble, low nanomolar PDE6D inhibitor (PDE6Di), Deltaflexin3, which has the lowest off-target activity as compared to three prominent reference compounds. Deltaflexin3 reduces Ras signaling and selectively decreases the growth of KRAS mutant and PDE6D-dependent cancer cells. We further show that PKG2-mediated phosphorylation of Ser181 lowers K-Ras binding to PDE6D. Thus, Deltaflexin3 combines with the approved PKG2 activator Sildenafil to more potently inhibit PDE6D/K-Ras binding, cancer cell proliferation, and microtumor growth. As observed previously, inhibition of Ras trafficking, signaling, and cancer cell proliferation remained overall modest. Our results suggest reevaluating PDE6D as a K-Ras surrogate target in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.
- Faculty of Technology, University of Novi Sad, 21000 Novi Sad, Serbia.
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
- Luxembourg Center for Systems Biomedicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.
- Bioinformatics Core, Department of Life Sciences and Medicine, University of Luxembourg, 4365 Esch-sur-Alzette, Luxembourg.
ORCID-Profile: Elisabeth Schaffner-Reckinger, Enrico Glaab, Daniel Kwaku Abankwa
Förderung
- Fonds National de la Recherche Luxembourg
- Bayer-Stiftungen
Zitieren
APA
Kaya, P., Schaffner-Reckinger, E., Manoharan, G. B., Vukic, V., Kiriazis, A., Ledda, M., Burgos Renedo, M., Pavic, K., Gaigneaux, A., Glaab, E., & Abankwa, D. K. (2024). An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02129
Vancouver
Kaya P, Schaffner-Reckinger E, Manoharan GB, Vukic V, Kiriazis A, Ledda M, et al. An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02129
BibTeX
@article{Kaya2024,
author = {Kaya, Pelin and Schaffner-Reckinger, Elisabeth and Manoharan, Ganesh Babu and Vukic, Vladimir and Kiriazis, Alexandros and Ledda, Mirko and Burgos Renedo, Maria and Pavic, Karolina and Gaigneaux, Anthoula and Glaab, Enrico and Abankwa, Daniel Kwaku},
title = {An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02129}
}
EUVIMED